Evidence map›Paper›PMID 31068386›Full record

ArticleThe oncologist2019

Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).

Megumi Furuta, Jun Sakakibara-Konishi, Hajime Kikuchi, Hiroshi Yokouchi, Hiroshi Nishihara, Hiroyuki Minemura, Masao Harada, Shigeo Yamazaki, Kenji Akie, Yuka Fujita and 11 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 12 institutions in 1 country.

Megumi FurutaDepartment of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Jun Sakakibara-KonishiDepartment of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan konishj@med.hokudai.ac.jp.
Hajime KikuchiFirst Department of Medicine, Obihiro Kosei Hospital, Obihiro, Japan.
Hiroshi YokouchiDepartment of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
Hiroshi NishiharaCancer Center, Keio University School of Medicine, Tokyo, Japan.
Hiroyuki MinemuraDepartment of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
Masao HaradaDepartment of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
Shigeo YamazakiDepartment of Thoracic Surgery, Keiyukai Sapporo Hospital, Sapporo, Japan.
Kenji AkieDepartment of Respiratory Disease, Sapporo City General Hospital, Sapporo, Japan.
Yuka FujitaDepartment of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center, Asahikawa, Japan.
Kei TakamuraFirst Department of Medicine, Obihiro Kosei Hospital, Obihiro, Japan.
Tetsuya KojimaDepartment of Medical Oncology, KKR Sapporo Medical Center, Sapporo, Japan.
Toshiyuki HaradaCenter for Respiratory Diseases, Japan Community Health Care Organization (JCHO) Hokkaido Hospital, Sapporo, Japan.
Yoshinori MinamiRespiratory Center, Asahikawa Medical University, Asahikawa, Japan.
Naomi WatanabeDepartment of Internal Medicine, Sunagawa City Medical Center, Sunagawa, Japan.
Satoshi OizumiDepartment of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
Hiroyuki SuzukiDepartment of Chest Surgery, Fukushima Medical University, Fukushima, Japan.
Masaharu NishimuraDepartment of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Hirotoshi Dosaka-AkitaDepartment of Medical Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Hiroshi IsobeDepartment of Medical Oncology, KKR Sapporo Medical Center, Sapporo, Japan.
Hokkaido Lung Cancer Clinical Study Group
Hokkaido University · JPAsahikawa Medical University · JPFukushima Medical University · JPNTT Medical Center · JPObihiro Kosei General Hospital · JPSapporo National Hospital · JPHokkaido hospital · JPKeio University · JPKeiyukai Sapporo Hospital · JPNational Hospital Organization Hokkaido Medical Center · JPSapporo City General Hospital · JPSunagawa City Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDelta-like protein 3 (DLL3) is a Notch ligand that has an important role in the tumorigenesis of small cell lung cancer (SCLC). Recently, rovalpituzumab tesirine (Rova-T), a DLL3-targeted antibody-drug conjugate, has been developed for treating SCLC. DLL3 is a transcriptional target of the achaete-scute homolog-1 (ASCL1) transcription factor, which is involved in pulmonary neuroendocrine cell development. However, the relationship between DLL3 and/or ASCL1 expression and the clinical features of SCLC remains unknown, especially for early-stage resected SCLC. This study aimed to investigate the expression of DLL3 and ASCL1 in resected SCLC samples using immunohistochemical analysis. MATERIALS AND

methodsWe collected 95 surgically resected SCLC samples, which were formalin fixed and paraffin embedded. Immunohistochemistry staining was performed to investigate the correlation between the expression of either DLL3 or ASCL1 and clinicopathological features of study patients.

resultsSeventy-seven (83%) of 93 immunohistochemically evaluable samples were positive for DLL3 (expression in ≥1% of tumor cells), and DLL3-high expression (≥75%) was observed in 44 samples (47%). Sixty-one (64%) of 95 samples were positive for ASCL1 (expression in ≥5% of tumor cells). A positive correlation was observed between DLL3 and ASCL1 expression. DLL3 and ASCL1 expression were not associated with survival in SCLC patients. DLL3 was more prevalent in patients with advanced clinical disease.

conclusionDLL3 and ASCL1 were highly expressed in patients with surgically resected SCLC. DLL3 and ASCL1 may be targets for the treatment of SCLC. IMPLICATIONS FOR PRACTICE: This article examines the relationship between delta-like protein 3 (DLL3) and achaete-scute homolog-1 (ASCL1) protein expression with the clinical features of 95 surgically resected small cell lung cancer (SCLC). DLL3 is attracting attention because rovalpituzumab tesirine (Rova-T), a DLL3-targeted antibody-drug conjugate, was developed recently. DLL3 and ASCL1 were highly expressed in patients with surgically resected SCLC. DLL3 and ASCL1 may be targets for the treatment of early-stage SCLC, including with Rova-T.

Indexed as

AgedAged, 80 and overBasic Helix-Loop-Helix ProteinsFemaleHumansImmunohistochemistryIntracellular Signaling Peptides and ProteinsKaplan-Meier EstimateLung NeoplasmsMaleMembrane ProteinsMiddle AgedSmall Cell Lung CarcinomaASCL1 protein, humanBasic Helix-Loop-Helix ProteinsDLL3 protein, humanIntracellular Signaling Peptides and ProteinsMembrane ProteinsAchaete‐scute homolog‐1Delta‐like protein 3ImmunohistochemistrySmall cell lung cancerSurgery

Identifiers

PMID31068386
PMCPMC6853124
OpenAlexW2944307155

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.